Article By:
IPO Candy
Thursday, November 5, 2015 10:30 AM EDT
GenSight is a smaller size biotech deal with Leerick, Evercore and Canaccord on the cover. The 4.6M shares are all primary with a $14 mid-point. Post-IPO there will be close to 19M shares with a market cap of $270m.